
Anna C Virgili

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2266782/publications.pdf

Version: 2024-02-01



ANNA C VIRCUI

#	Article	IF	CITATIONS
1	Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy. Journal of Personalized Medicine, 2022, 12, 618.	2.5	1
2	Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients Farmacia Hospitalaria, 2021, 45, 5-10.	0.6	0
3	ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in Pharmacology, 2020, 11, 973.	3.5	14
4	Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2245.	3.7	2
5	Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer, 2020, 20, 99.	2.6	31
6	Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. British Journal of Cancer, 2019, 120, 190-195.	6.4	31
7	Relevance of <i>CYP3A4*20</i> , <i>UGT1A1*37</i> and <i>UGT1A1*28</i> variants in irinotecanâ€induced severe toxicity. British Journal of Clinical Pharmacology, 2018, 84, 1389-1392.	2.4	19
8	Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. Pharmacogenomics Journal, 2018, 18, 556-564.	2.0	7
9	Brain metastases in colorectal cancer: prognostic factors and survival analysis. International Journal of Colorectal Disease, 2018, 33, 1517-1523.	2.2	11